Cell & Gene: The Podcast
Cell & Gene: The Podcast
Inside a Breakthrough HER2 Immunotherapy for PMO with OS Therapies’ Paul Romness
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
We love to hear from our listeners. Send us a message.
In episode 122 of Cell & Gene: The Podcast, Host Erin Harris talks to Paul Romness, CEO of OS Therapies, to learn the company’s mission to address the severe unmet need in pulmonary metastatic osteosarcoma (PMO), a rare pediatric cancer with no established standard of care once it metastasizes. Romness explains how OS Therapies’ off-the-shelf HER2-targeted immunotherapy aims to significantly improve outcomes by stimulating a robust immune response with minimal side effects. He highlights results from a multicenter Phase 2B trial showing markedly improved overall survival rates compared to historical outcomes, details the company’s constructive regulatory interactions with the FDA, and underscores the value of comparative canine biomarkers in development.
Subscribe to the podcast!
Apple | Spotify | YouTube
Visit my website: Cell & Gene
Connect with me on LinkedIn
Podcasts we love
Check out these other fine podcasts recommended by us, not an algorithm.